[HTML][HTML] Advances in developing therapeutic strategies for Alzheimer's disease
Alzheimer's disease (AD) is a progressive deterioration of brain function, initially
characterized by cognitive deficits, with loss of recent memory and language ability …
characterized by cognitive deficits, with loss of recent memory and language ability …
Liposome delivery systems for the treatment of Alzheimer's disease
C Ross, M Taylor, N Fullwood… - International journal of …, 2018 - Taylor & Francis
Alzheimer's disease (AD) will affect around 115 million people worldwide by the year 2050.
It is associated with the accumulation of misfolded and aggregated proteins (β-amyloid and …
It is associated with the accumulation of misfolded and aggregated proteins (β-amyloid and …
Advances in nanocarriers enabled brain targeted drug delivery across blood brain barrier
G Sharma, AR Sharma, SS Lee, M Bhattacharya… - International journal of …, 2019 - Elsevier
The blood brain barrier (BBB) offers protection to the central nervous system (CNS) by
maintaining homeostasis. Besides restricting the entry of harmful xenobiotics and …
maintaining homeostasis. Besides restricting the entry of harmful xenobiotics and …
Rationally designed peptides and peptidomimetics as inhibitors of amyloid-β (Aβ) aggregation: Potential therapeutics of Alzheimer's disease
Alzheimer's disease (AD) is a progressive neurodegenerative disease with no clinically
accepted treatment to cure or halt its progression. The worldwide effort to develop peptide …
accepted treatment to cure or halt its progression. The worldwide effort to develop peptide …
Benzofuran and indole: promising scaffolds for drug development in Alzheimer's disease
Alzheimer's disease (AD) is a progressive neurodegenerative disease with no clinically
accepted treatment to cure or halt its progression. The Food and Drug Administration has …
accepted treatment to cure or halt its progression. The Food and Drug Administration has …
Peptides as pharmacological carriers to the brain: promises, shortcomings and challenges
S Parrasia, I Szabò, M Zoratti… - Molecular …, 2022 - ACS Publications
Central nervous system (CNS) diseases are among the most difficult to treat, mainly
because the vast majority of the drugs fail to cross the blood-brain barrier (BBB) or to reach …
because the vast majority of the drugs fail to cross the blood-brain barrier (BBB) or to reach …
Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases
MI Teixeira, CM Lopes, MH Amaral, PC Costa - European journal of …, 2020 - Elsevier
The central nervous system (CNS) is vulnerable to pathologic processes that lead to the
development of neurodegenerative disorders like Alzheimer's, Parkinson's and Huntington's …
development of neurodegenerative disorders like Alzheimer's, Parkinson's and Huntington's …
Advances in nanomedicines for diagnosis of central nervous system disorders
In spite of a great improvement in medical health services and an increase in lifespan, we
have witnessed a skyrocket increase in the incidence of central nervous system (CNS) …
have witnessed a skyrocket increase in the incidence of central nervous system (CNS) …
[HTML][HTML] Recent applications of retro-inverso peptides
Natural and de novo designed peptides are gaining an ever-growing interest as drugs
against several diseases. Their use is however limited by the intrinsic low bioavailability and …
against several diseases. Their use is however limited by the intrinsic low bioavailability and …
Dual functionalized liposome-mediated gene delivery across triple co-culture blood brain barrier model and specific in vivo neuronal transfection
B dos Santos Rodrigues, H Oue, A Banerjee… - Journal of controlled …, 2018 - Elsevier
Gene therapy has become a promising approach for neurodegenerative disease treatment,
however there is an urgent need to develop an efficient gene carrier to transport gene …
however there is an urgent need to develop an efficient gene carrier to transport gene …